# A Study to Evaluate ACT-132577 in Healthy Male Subjects

> **NCT03100591** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** 14C-radiolabeled ACT-132577

## Key facts

- **NCT ID:** NCT03100591
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-28
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-18
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100591, "A Study to Evaluate ACT-132577 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03100591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*